These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8743042)

  • 1. Primary and secondary prevention of myocardial infarction.
    Borghi C; Ambrosioni E
    Clin Exp Hypertens; 1996; 18(3-4):547-58. PubMed ID: 8743042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic therapies after myocardial infarction.
    Rapaport E; Gheorghiade M
    Am J Med; 1996 Oct; 101(4A):4A61S-69S; discussion 4A69S-70S. PubMed ID: 8900339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment after myocardial infarction].
    Beurrier D; Danchin N
    Presse Med; 1994 Feb; 23(8):380-4. PubMed ID: 7911570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice.
    Fishkind D; Paris BE; Aronow WS
    J Am Geriatr Soc; 1997 Jul; 45(7):809-12. PubMed ID: 9215330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials.
    Yusuf S; Lessem J; Jha P; Lonn E
    J Hypertens Suppl; 1993 Jun; 11(4):S61-73. PubMed ID: 8104243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention of myocardial infarction: role of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors.
    Frishman WH; Cheng A
    Am Heart J; 1999 Apr; 137(4 Pt 2):S25-S34. PubMed ID: 10097243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus.
    Chowdhury TA; Lasker SS; Dyer PH
    J Intern Med; 1999 Jun; 245(6):565-70. PubMed ID: 10395185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of postmyocardial infarction in the elderly patient.
    Forman R; Aronow WS
    Clin Geriatr Med; 1996 Feb; 12(1):169-80. PubMed ID: 8653656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
    Barron HV; Michaels AD; Maynard C; Every NR
    J Am Coll Cardiol; 1998 Aug; 32(2):360-7. PubMed ID: 9708461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary prevention in acute myocardial infarction.
    Mehta RH; Eagle KA
    BMJ; 1998 Mar; 316(7134):838-42. PubMed ID: 9549457
    [No Abstract]   [Full Text] [Related]  

  • 11. Additive beneficial effects of beta blockers in the prevention of symptomatic heart failure.
    Genovesi Ebert A; Colivicchi F; Malvezzi Caracciolo M; Riccio C
    Monaldi Arch Chest Dis; 2009 Mar; 72(1):18-22. PubMed ID: 19645208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction.
    Gutstein DE; Fuster V
    Clin Cardiol; 1998 Mar; 21(3):161-8. PubMed ID: 9541759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonlipid primary and secondary prevention strategies for coronary heart disease.
    Maron DJ
    Clin Cardiol; 1996 May; 19(5):419-23. PubMed ID: 8723603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.
    EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events
    Lancet; 2001 Mar; 357(9261):995-1001. PubMed ID: 11293642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful implementation of guidelines for encouraging the use of beta blockers in patients after acute myocardial infarction.
    Sarasin FP; Maschiangelo ML; Schaller MD; Héliot C; Mischler S; Gaspoz JM
    Am J Med; 1999 May; 106(5):499-505. PubMed ID: 10335720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists in treatment of elderly patients with acute myocardial infarction.
    Aronow WS
    Coron Artery Dis; 2000 Jun; 11(4):331-8. PubMed ID: 10860176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man.
    Lemmer B
    Pharmacol Ther; 2006 Sep; 111(3):629-51. PubMed ID: 16480770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction.
    Shlipak MG; Browner WS; Noguchi H; Massie B; Frances CD; McClellan M
    Am J Med; 2001 Apr; 110(6):425-33. PubMed ID: 11331052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of older persons after myocardial infarction.
    Aronow WS
    J Am Geriatr Soc; 1998 Nov; 46(11):1459-68. PubMed ID: 9809771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital.
    Mitra S; Findley K; Frohnapple D; Mehta JL
    Clin Cardiol; 2002 Jan; 25(1):16-8. PubMed ID: 11808833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.